Skip to main content

Table 3 Comparison of clinical characteristics according to APOE genotype in elderly patients with schizophrenia

From: Low prevalence of lipid metabolism abnormalities in APOE ε2-genotype and male patients 60 years or older with schizophrenia

Item   APOE ε2(n = 40) APOE ε3(n = 205) APOE ε4(n = 49) x 2 /F P-value
Men (%)   23 (57.5%) 109 (53.2%) 26 (53.1%) 0.263 0.877
Age (years)   67.65 ± 7.17 67.10 ± 6.54 68.00 ± 6.58 0.422 0.656
Overweight status (%)   18 (45.0%) 98 (47.8%) 21 (42.9%) 0.437 0.804
History of disease Diabetes (%) 11 (27.5%) 52 (25.4%) 12 (24.5%) 0.112 0.945
High blood pressure (%) 11 (27.5%) 78 (38.0%) 19 (38.8%) 1.708 0.426
Drug use* Atypical antipsychotic use (%) 36 (90.0%) 179 (87.3%) 45 (91.8%)   0.751#
Chlorpromazine equivalent dose (mg) 322.88 ± 320.06 318.52 ± 254.79 361.98 ± 371.20 0.459 0.490
Lipid-lowering mediation use (%) 1 (2.5%) 6 (2.9%) 7 (14.3%)   0.006#
Glucose-lowering medication use (%) 9 (22.5%) 43 (21.0%) 12 (24.5%) 0.296 0.863
Serum biochemical indices& Triglycerides (mmol/L) 1.35 ± 0.81 1.38 ± 0.84 1.43 ± 0.80 0.062 0.940
Cholesterol (mmol/L) 4.38 ± 0.91 4.74 ± 0.91 4.94 ± 1.47 2.994 0.052
High-density lipoprotein (mmol/L) 1.36 ± 0.35 1.29 ± 0.41 1.25 ± 0.45 0.812 0.445
Low-density lipoprotein (mmol/L) 2.34 ± 0.63 2.83 ± 0.75 2.85 ± 0.98 7.038 0.001
Plasma glucose (mmol/L) 5.58 ± 1.40 5.50 ± 1.49 5.27 ± 0.89 1.198 0.303
  1. Note: APOE genotypes were divided into three groups: an APOE ε2 group (ε2/ε2 and ε2/ε3), an APOE ε3 group (ε3/ε3), and an APOE ε4 group (ε3/ε4 and ε4/ε4)
  2. #: Fisher’s Exact Test
  3. *: Different antipsychotics were converted to chlorpromazine equivalent doses
  4. &: Plasma glucose was compared among the three groups with glucose-lowering medication use as a covariate. Serum lipids were compared among the three groups with lipid-lowering medication use as a covariate